Skip to main content


Firm News

Mayer Brown represents Adaptimmune Therapeutics PLC on IPO

7 May 2015
Mayer Brown announced today that it represented Adaptimmune Therapeutics PLC on its approximately $191.3 million initial public offering, advising the company on all aspects of US and UK corporate and securities laws and related disciplines. Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform.

In 2014, Mayer Brown represented Adaptimmune Limited on its $104 million Series A financing round led by a group of leading public and private healthcare focused venture funds and leading mutual funds, including New Enterprise Associates, OrbiMed, Fidelity and Wellington, marking one of the largest Series A biopharmaceutical investment rounds in history.

The Mayer Brown team was led by Corporate & Securities partner David Bakst (New York) and included: Corporate & Securities partner Richard Smith (London) and associates Mandee Lee, George Rudy, Stephanie Grajales (all New York) and Megan Paul (London); Tax Transactions & Consulting partners James Hill (London) and Jason Bazar and associate Moe Worsley (both New York); Employment & Benefits partners Andrew Stanger (London) and James Williams (Chicago); Intellectual Property partner Rich Assmus (Chicago) and associate Neil DuChez (New York); and Litigation & Dispute Resolution partner Elizabeth Mann (Los Angeles).

The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.